Attached files
| file | filename |
|---|---|
| EX-3.1 - EXHIBIT 3.1 - Pharmamed, Inc. | pharmamed-s1ex3z1.htm |
| EX-23.1 - EXHIBIT 23.1 - Pharmamed, Inc. | pharmamed-s1ex23z1.htm |
| EX-99.2 - EXHIBIT 99.2 - Pharmamed, Inc. | pharmamed-s1ex99z2.htm |
| S-1 - FORM S-1 - Pharmamed, Inc. | pharmamed-s1.htm |
| EX-3.2 - EXHIBIT 3.2 - Pharmamed, Inc. | pharmamed-s1ex3z2.htm |
| EX-99.1 - EXHIBIT 99.1 - Pharmamed, Inc. | pharmamed-s1ex99z1.htm |
| Paritz |
& Company, P.A |
15 Warren Street, Suite 25 Hackensack, New Jersey 07601 Phone: (201) 342-7753 Fax: (201) 342-7598
| |
| Certified Public Accountants | |||
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors
Pharmamed, Inc.
We have audited the accompanying balance sheet of Pharmamed, Inc. as of June 30, 2014 and the related statements of operations, stockholders’ deficit and cash flows for the period April 25, 2014 (Inception) to June 30, 2014. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has not generated any revenues since inception, has sustained a net loss of $4,865 since inception, and has a stockholders’ deficit of $2,886 at June 30, 2014. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Pharmamed, Inc. as of June 30, 2014, and the results of its operations and cash flows for the period April 25, 2014 (Inception) to June 30, 2014 in conformity with accounting principles generally accepted in the United States of America.
/S/Paritz & Company, P.A.
Hackensack, New Jersey
July 7, 2014